<p><em>擬議對總部位於德國的 PAD Aviation 進行戰略投資，這是一家頂級的歐洲私人航空運營商，旨在為 TransMedics 在歐洲建立專門的器官移植空中物流網絡奠定基礎</em></p>
<p>, /PRNewswire/ -- TransMedics Group, Inc.（&#34;TransMedics&#34;）（納斯達克：TMDX），一家正在改變終末期肺、心臟和肝臟衰竭患者器官移植治療的醫療技術公司，今天宣佈已與 PAD Aviation 達成最終協議，計劃進行投資，PAD Aviation 是一家總部位於德國的頂級私人航空運營商。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/676128/TransMedics_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/676128/TransMedics_Logo.jpg"/></p>
<p>擬議的戰略投資旨在支持 TransMedics 持續努力，通過在歐洲建立專門的器官移植空中和地面物流網絡，複製成功的美國 NOP 和物流模式，以支持其 OCS™灌注平台和臨牀服務，目標是擴大對捐贈器官的獲取並增加需要移植的患者在歐盟的移植數量。</p>
<p>&#34;在歐洲建立專門的移植空中物流網絡是支持我們歐洲 NOP 戰略的必要第一步，旨在將我們的 OCS 技術和綜合物流模式的全部好處帶給需要移植的歐洲患者。我們已經在意大利積極建立我們的存在，並計劃逐步擴大對捐贈器官的獲取並增加歐洲患者的移植數量。我們期待與 PAD 團隊合作，在未來幾年推進這一願景，&#34;TransMedics 的總裁兼首席執行官 Waleed Hassanein 博士表示。</p>
<p>擬議的戰略投資需滿足雙方在最終協議（&#34;協議&#34;）中規定的成交條件以及適用的監管條件。TransMedics 預計交易將在 2026 年晚些時候完成，但無法保證擬議交易將會完成。財務條款未予披露。</p>
<p><strong>關於 PAD Aviation service GmbH</strong> PAD Aviation 是一家領先的歐洲商務航空運營商，獨立於商業航空公司。該公司在德國帕德博恩的 24/7 樞紐運營，提供最大靈活性，特別適用於器官運輸等時間緊迫的任務。PAD Aviation 的飛機可以迅速到達歐洲各地的目的地。該公司運營現代化機隊，包括九架 Embraer Phenom 300 飛機，並僱傭超過 40 名經過高度培訓和類型認證的飛行員。PAD Aviation 持有有效的 EASA 航空運營證書（AOC）。</p>
<p><strong>關於 TransMedics Group, Inc.</strong> TransMedics 是全球便攜式體外温灌注和捐贈器官評估的領導者。公司總部位於馬薩諸塞州安多佛，成立的目的是解決器官移植中對更多和更好器官的未滿足需求，並開發了技術以保持器官質量、在移植前評估器官的可行性，並可能增加捐贈器官在終末期心臟、肺和肝臟衰竭治療中的利用率。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含前瞻性聲明。這些前瞻性聲明涉及各種事項，包括但不限於根據協議對 PAD Aviation 的擬議戰略投資及其預期時間和完成情況；擬議戰略投資的預期好處，包括建立專門的空中物流基礎設施以支持歐盟的 OCS 和 NOP 平台；我們在歐洲複製美國 NOP 模式的戰略，包括通過專門的空中和地面物流；航空許可、認證和運營基礎設施在支持歐洲 NOP 中的預期作用；我們在意大利的持續商業運營；以及我們更廣泛的國際擴展計劃及相關成本。為此，所有非歷史事實的聲明均為前瞻性聲明。&#34;相信&#34;、&#34;可能&#34;、&#34;將&#34;、&#34;估計&#34;、&#34;繼續&#34;、&#34;預期&#34;、&#34;打算&#34;、&#34;期望&#34;、&#34;應該&#34;、&#34;可以&#34;、&#34;目標&#34;、&#34;預測&#34;、&#34;尋求&#34;及類似表達旨在識別前瞻性聲明。</p>
<p>這些前瞻性聲明受到多種風險和不確定性的影響。管理層無法預測所有風險，也無法評估所有因素的影響或任何因素或因素組合可能導致的實際結果與我們可能做出的任何前瞻性聲明中所包含或暗示的結果之間的重大差異。在這些風險和不確定性的背景下，本新聞稿中討論的前瞻性事件和情況可能不會發生，實際結果可能與預期或前瞻性聲明中暗示的結果存在重大和不利的差異。一些可能導致實際結果不同的關鍵因素包括：與對 PAD Aviation 的待定戰略投資相關的風險和不確定性，包括可能導致協議終止的任何事件、變化或其他情況的發生；交易關閉條件未能及時或根本無法獲得的風險；交易（或其公告或待定狀態）對與關聯方、客户、製造商、供應商、員工、其他商業夥伴或政府實體的關係的影響；交易成本；交易可能分散管理層對 TransMedics 持續業務運營的關注或以其他方式干擾 TransMedics 持續業務運營的風險；與將 PAD Aviation 與 TransMedics 整合相關的風險，包括保留關鍵員工的風險；經營航空業務的風險；進一步發展和增強國家 OCS 計劃的能力相關的風險；以及在 TransMedics 向證券交易委員會（&#34;SEC&#34;）提交的文件中描述的其他因素，包括在 TransMedics 截至 2025 年 12 月 31 日的年度報告的&#34;風險因素&#34;標題下的內容，該報告於 2026 年 2 月 24 日提交給 SEC，以及我們後續向 SEC 提交的類似披露。本新聞稿中的前瞻性聲明僅在本新聞稿日期時有效。可能導致我們實際結果不同的因素或事件可能會不時出現，我們無法預測所有這些因素。除非適用法律要求，否則我們不承擔更新任何前瞻性聲明的義務，無論是由於新信息、未來發展還是其他原因。</p>
<p><strong>投資者聯繫：</strong> Brian Johnston</p>
<p>Gilmartin Group</p>
<p>Investors@transmedics.com</p>
<p>來源：TransMedics Group, Inc.</p>

TMDX

<p>TransMedics Group, Inc. 宣佈對總部位於德國的 PAD Aviation 進行戰略投資，以建立一個專門的器官移植航空物流網絡，覆蓋整個歐洲。該計劃旨在複製美國成功的模式，增強需要器官的患者對捐贈器官的獲取。此項投資需滿足成交條件和監管批准，預計將在 2026 年完成。TransMedics 專注於擴大在歐洲的業務，特別是在意大利，以增加移植數量並改善器官移植的質量</p>

<p><em>Proposed strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, intended to lay the foundation for TransMedics to establish a dedicated organ transplantation air logistics network across Europe</em></p>
<div class="lb-trans"><p><em>擬議對總部位於德國的 PAD Aviation 進行戰略投資，這是一家頂級的歐洲私人航空運營商，旨在為 TransMedics 在歐洲建立專門的器官移植空中物流網絡奠定基礎</em></p>
</div><p>, /PRNewswire/ -- TransMedics Group, Inc. (&#34;TransMedics&#34;) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it has entered into a definitive agreement to invest in PAD Aviation, a premier Germany-based private aviation operator.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- TransMedics Group, Inc.（&#34;TransMedics&#34;）（納斯達克：TMDX），一家正在改變終末期肺、心臟和肝臟衰竭患者器官移植治療的醫療技術公司，今天宣佈已與 PAD Aviation 達成最終協議，計劃進行投資，PAD Aviation 是一家總部位於德國的頂級私人航空運營商。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/676128/TransMedics_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/676128/TransMedics_Logo.jpg"/></p>
<p>The proposed strategic investment is intended to support TransMedics' ongoing efforts to replicate the successful U.S. NOP and logistics model by building a dedicated organ transplantation air and ground logistics network in Europe in support of its OCS™ perfusion platform and clinical services, with the goal of expanding access to donor organs and increasing transplant volumes for patients in need across the European Union.</p>
<div class="lb-trans"><p>擬議的戰略投資旨在支持 TransMedics 持續努力，通過在歐洲建立專門的器官移植空中和地面物流網絡，複製成功的美國 NOP 和物流模式，以支持其 OCS™灌注平台和臨牀服務，目標是擴大對捐贈器官的獲取並增加需要移植的患者在歐盟的移植數量。</p>
</div><p>&#34;Building a dedicated transplant air logistics network in Europe is a necessary first step to supporting our European NOP strategy to bring the full benefits of our OCS technology and integrated logistics model to European patients in need of transplantation. We are already actively building our presence in Italy and our sights are set on expanding access to donor organs and increasing transplant volumes for patients across Europe over time. We look forward to working with the PAD team to advance this vision over the years ahead,&#34; said Waleed Hassanein, M.D., President and Chief Executive Officer of TransMedics.</p>
<div class="lb-trans"><p>&#34;在歐洲建立專門的移植空中物流網絡是支持我們歐洲 NOP 戰略的必要第一步，旨在將我們的 OCS 技術和綜合物流模式的全部好處帶給需要移植的歐洲患者。我們已經在意大利積極建立我們的存在，並計劃逐步擴大對捐贈器官的獲取並增加歐洲患者的移植數量。我們期待與 PAD 團隊合作，在未來幾年推進這一願景，&#34;TransMedics 的總裁兼首席執行官 Waleed Hassanein 博士表示。</p>
</div><p>The proposed strategic investment is subject to the satisfaction of closing conditions specified in the definitive agreement between the parties (the &#34;Agreement&#34;) as well as applicable regulatory conditions. TransMedics expects the transaction to close later in 2026 but can provide no assurance that the proposed transaction will be consummated. Financial terms are not being disclosed.</p>
<div class="lb-trans"><p>擬議的戰略投資需滿足雙方在最終協議（&#34;協議&#34;）中規定的成交條件以及適用的監管條件。TransMedics 預計交易將在 2026 年晚些時候完成，但無法保證擬議交易將會完成。財務條款未予披露。</p>
</div><p><strong>About PAD Aviation service GmbH</strong> PAD Aviation is a leading European business aviation operator, independent of commercial airlines. The company operates from its 24/7 hub in Paderborn, Germany, offering maximum flexibility—particularly for time-critical missions such as organ transport. From its centrally located base, PAD Aviation's aircraft can rapidly reach destinations across Europe. The company operates a modern fleet, including nine Embraer Phenom 300 aircraft, and employs more than 40 highly trained and type-rated pilots. PAD Aviation holds a valid EASA Air Operator Certificate (AOC).</p>
<div class="lb-trans"><p><strong>關於 PAD Aviation service GmbH</strong> PAD Aviation 是一家領先的歐洲商務航空運營商，獨立於商業航空公司。該公司在德國帕德博恩的 24/7 樞紐運營，提供最大靈活性，特別適用於器官運輸等時間緊迫的任務。PAD Aviation 的飛機可以迅速到達歐洲各地的目的地。該公司運營現代化機隊，包括九架 Embraer Phenom 300 飛機，並僱傭超過 40 名經過高度培訓和類型認證的飛行員。PAD Aviation 持有有效的 EASA 航空運營證書（AOC）。</p>
</div><p><strong>About TransMedics Group, Inc.</strong> TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.</p>
<div class="lb-trans"><p><strong>關於 TransMedics Group, Inc.</strong> TransMedics 是全球便攜式體外温灌注和捐贈器官評估的領導者。公司總部位於馬薩諸塞州安多佛，成立的目的是解決器官移植中對更多和更好器官的未滿足需求，並開發了技術以保持器官質量、在移植前評估器官的可行性，並可能增加捐贈器官在終末期心臟、肺和肝臟衰竭治療中的利用率。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains forward-looking statements. These forward-looking statements address various matters, including, among other things, the proposed strategic investment in PAD Aviation pursuant to the Agreement and the expected timing and consummation thereof; the anticipated benefits of the proposed strategic investment, including the establishment of dedicated air logistics infrastructure to support the OCS and NOP platforms in the European Union; our strategy of replicating our U.S. NOP model in Europe, including through dedicated air and ground logistics; the expected role of the aviation licensing, certifications, and operational infrastructure in supporting the European NOP; our ongoing commercial operations in Italy; and our broader international expansion plans and the costs related thereto. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words &#34;believe,&#34; &#34;may,&#34; &#34;will,&#34; &#34;estimate,&#34; &#34;continue,&#34; &#34;anticipate,&#34; &#34;intend,&#34; &#34;expect,&#34; &#34;should,&#34; &#34;could,&#34; &#34;target,&#34; &#34;predict,&#34; &#34;seek&#34; and similar expressions are intended to identify forward-looking statements.</p>
<div class="lb-trans"><p>本新聞稿包含前瞻性聲明。這些前瞻性聲明涉及各種事項，包括但不限於根據協議對 PAD Aviation 的擬議戰略投資及其預期時間和完成情況；擬議戰略投資的預期好處，包括建立專門的空中物流基礎設施以支持歐盟的 OCS 和 NOP 平台；我們在歐洲複製美國 NOP 模式的戰略，包括通過專門的空中和地面物流；航空許可、認證和運營基礎設施在支持歐洲 NOP 中的預期作用；我們在意大利的持續商業運營；以及我們更廣泛的國際擴展計劃及相關成本。為此，所有非歷史事實的聲明均為前瞻性聲明。&#34;相信&#34;、&#34;可能&#34;、&#34;將&#34;、&#34;估計&#34;、&#34;繼續&#34;、&#34;預期&#34;、&#34;打算&#34;、&#34;期望&#34;、&#34;應該&#34;、&#34;可以&#34;、&#34;目標&#34;、&#34;預測&#34;、&#34;尋求&#34;及類似表達旨在識別前瞻性聲明。</p>
</div><p>These forward-looking statements are subject to a number of risks and uncertainties. Management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: risks and uncertainties related to the pending strategic investment in PAD Aviation, including the occurrence of any event, change or other circumstance that could give rise to the termination of the Agreement; the risk that conditions to closing of the transaction are not obtained in a timely manner or at all; the effects of the transaction (or the announcement or pendency thereof) on relationships with associates, customers, manufacturers, suppliers, employees, other business partners or governmental entities; transaction costs; the risk that the transaction will divert management's attention from TransMedics' ongoing business operations or otherwise disrupts TransMedics' ongoing business operations; risks related to the ability to integrate PAD Aviation with TransMedics, including retaining key employees; risks related to operating an aviation business; risks related to the ability to further grow and enhance the National OCS Program; and other factors described in TransMedics' filings with the Securities and Exchange Commission (the &#34;SEC&#34;), including under the heading &#34;Risk Factors&#34; in TransMedics' Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026, and comparable disclosure in our subsequent filings with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.</p>
<div class="lb-trans"><p>這些前瞻性聲明受到多種風險和不確定性的影響。管理層無法預測所有風險，也無法評估所有因素的影響或任何因素或因素組合可能導致的實際結果與我們可能做出的任何前瞻性聲明中所包含或暗示的結果之間的重大差異。在這些風險和不確定性的背景下，本新聞稿中討論的前瞻性事件和情況可能不會發生，實際結果可能與預期或前瞻性聲明中暗示的結果存在重大和不利的差異。一些可能導致實際結果不同的關鍵因素包括：與對 PAD Aviation 的待定戰略投資相關的風險和不確定性，包括可能導致協議終止的任何事件、變化或其他情況的發生；交易關閉條件未能及時或根本無法獲得的風險；交易（或其公告或待定狀態）對與關聯方、客户、製造商、供應商、員工、其他商業夥伴或政府實體的關係的影響；交易成本；交易可能分散管理層對 TransMedics 持續業務運營的關注或以其他方式干擾 TransMedics 持續業務運營的風險；與將 PAD Aviation 與 TransMedics 整合相關的風險，包括保留關鍵員工的風險；經營航空業務的風險；進一步發展和增強國家 OCS 計劃的能力相關的風險；以及在 TransMedics 向證券交易委員會（&#34;SEC&#34;）提交的文件中描述的其他因素，包括在 TransMedics 截至 2025 年 12 月 31 日的年度報告的&#34;風險因素&#34;標題下的內容，該報告於 2026 年 2 月 24 日提交給 SEC，以及我們後續向 SEC 提交的類似披露。本新聞稿中的前瞻性聲明僅在本新聞稿日期時有效。可能導致我們實際結果不同的因素或事件可能會不時出現，我們無法預測所有這些因素。除非適用法律要求，否則我們不承擔更新任何前瞻性聲明的義務，無論是由於新信息、未來發展還是其他原因。</p>
</div><p><strong>Investor Contact:</strong> Brian Johnston</p>
<div class="lb-trans"><p><strong>投資者聯繫：</strong> Brian Johnston</p>
</div><p>Gilmartin Group</p>
<div class="lb-trans"><p>Gilmartin Group</p>
</div><p>Investors@transmedics.com</p>
<div class="lb-trans"><p>Investors@transmedics.com</p>
</div><p>SOURCE TransMedics Group, Inc.</p>
<div class="lb-trans"><p>來源：TransMedics Group, Inc.</p>
</div>

TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH | TMDX Stock News

TransMedics 集團宣佈計劃通過戰略投資 PAD 航空服務有限公司，創建首個專門的歐洲移植物流網絡 | TMDX 股票新聞